Evaluation of Seven Tumour Markers in Pleural Fluid for the Diagnosis of Malignant Effusions

Overview

Journal Br J Cancer

Specialty Oncology

Date 1999 Nov 27

PMID 10576665

Citations 28

Authors

M Miedouge

P ROUZAUD

G Salama

M C Pujazon

C Vincent

M A Mauduyt

J Reyre

P Carles

G Serre

Affiliations

Soon will be listed here.

Abstract

Carcinoembryonic antigen (CEA), carbohydrate antigens 15-3, 19-9 and 72-4 (CA 15-3, CA 19-9 and CA 72-4), cytokeratin 19 fragments (CYFRA 21-1), neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC) were evaluated in pleural fluid for the diagnosis of malignant effusions. With a specificity of 99%, determined in a series of 121 benign effusions, the best individual diagnostic sensitivities in the whole series of 215 malignant effusions or in the subgroup of adenocarcinomas were observed with CEA, CA 15-3 and CA 72-4. As expected, a high sensitivity was obtained with SCC in squamous cell carcinomas and with NSE in small-cell lung carcinomas. CYFRA and/or CA 15-3 were frequently increased in mesotheliomas. Discriminant analysis showed that the optimal combination for diagnosis of non-lymphomatous malignant effusions was CEA + CA 15-3 + CYFRA + NSE: sensitivity of 94.4% with an overall specificity of 95%. In malignant effusions with a negative cytology, 83.9% were diagnosed using this association. The association CYFRA + NSE + SCC was able to discriminate adenocarcinomas from small-cell lung cancers. Regarding their sensitivity and their complementarity, CEA, CA 15-3, CYFRA 21-1, NSE and SCC appear to be very useful to improve the diagnosis of malignant pleural effusions.

Citing Articles

Tumor Markers in Pleural Fluid: A Comprehensive Study on Diagnostic Accuracy.

Aleksiev V, Markov D, Bechev K Diagnostics (Basel). 2025; 15(2).

PMID: 39857088 PMC: 11765104. DOI: 10.3390/diagnostics15020204.

Pleural fluid carbohydrate antigen 72-4 and malignant pleural effusion: a diagnostic test accuracy study.

Cao X, Yan L, Jiang T, Huang J, Chen H, Porcel J Ther Adv Respir Dis. 2024; 18:17534666231222333.

PMID: 38189269 PMC: 10775747. DOI: 10.1177/17534666231222333.

Immunocytochemistry of effusions: Processing and commonly used immunomarkers.

Shidham V, Janikowski B Cytojournal. 2022; 19:6.

PMID: 35541029 PMC: 9079319. DOI: 10.25259/CMAS_02_15_2021.

Pleural biomarkers in diagnostics of malignant pleural effusion: a narrative review.

Zhang M, Yan L, Lippi G, Hu Z Transl Lung Cancer Res. 2021; 10(3):1557-1570.

PMID: 33889529 PMC: 8044497. DOI: 10.21037/tlcr-20-1111.

Diagnostic utility of pleural fluid carcinoembryonic antigen in patients with exudative pleural effusion.

Krishnan V, Kunoor A, Keechilath P, Mehta A Lung India. 2021; 38(2):139-143.

PMID: 33687007 PMC: 8098895. DOI: 10.4103/lungindia.lungindia_196_20.

References

Rittgers R, Loewenstein M, Feinerman A, Kupchik H, Marcel B, Koff R . Carcinoembryonic antigen levels in benign and malignant pleural effusions. Ann Intern Med. 1978; 88(5):631-4. DOI: 10.7326/0003-4819-88-5-631. View

Doweck I, Barak M, Greenberg E, Uri N, Kellner J, Lurie M . Cyfra 21-1. A new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg. 1995; 121(2):177-81. DOI: 10.1001/archotol.1995.01890020039009. View

Asseo P, Tracopoulos G . Simultaneous enzyme immunoassay of carcinoembryonic antigen in pleural effusion and serum. Am J Clin Pathol. 1982; 77(1):66-71. DOI: 10.1093/ajcp/77.1.66. View

Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Cavaliere F . CA 72-4 serum marker--a new tool in the management of carcinoma patients. Cancer Invest. 1995; 13(2):227-38. DOI: 10.3109/07357909509011692. View

Satoh H, Sumi M, Yagyu H, Ishikawa H, Suyama T, Naitoh T . Clinical evaluation of CYFRA 21-1 in malignant pleural fluids. Oncology. 1995; 52(3):211-4. DOI: 10.1159/000227459. View

Niklinski J, Furman M . Clinical tumour markers in lung cancer. Eur J Cancer Prev. 1995; 4(2):129-38. DOI: 10.1097/00008469-199504000-00002. View

Peto J, Hodgson J, Matthews F, Jones J . Continuing increase in mesothelioma mortality in Britain. Lancet. 1995; 345(8949):535-9. DOI: 10.1016/s0140-6736(95)90462-x. View

Fenton K, Richardson J . Diagnosis and management of malignant pleural effusions. Am J Surg. 1995; 170(1):69-74. DOI: 10.1016/s0002-9610(99)80257-8. View

Plebani M, Basso D, Navaglia F, De Paoli M, Tommasini A, Cipriani A . Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?. Br J Cancer. 1995; 72(1):170-3. PMC: 2034156. DOI: 10.1038/bjc.1995.296. View

10.

Harris R, Kavuru M, Rice T, KIRBY T . The diagnostic and therapeutic utility of thoracoscopy. A review. Chest. 1995; 108(3):828-41. DOI: 10.1378/chest.108.3.828. View

11.

Lembersky B, Thomas L . Metastases of unknown primary site. Med Clin North Am. 1996; 80(1):153-71. DOI: 10.1016/s0025-7125(05)70433-8. View

12.

Soletormos G, Nielsen D, Schioler V, Skovsgaard T, Dombernowsky P . Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. Clin Chem. 1996; 42(4):564-75. View

13.

Nyberg P, Soderblom T, Pettersson T, Riska H, Klockars M, Linko L . Neurone-specific enolase levels in pleural effusions in patients with rheumatoid arthritis. Thorax. 1996; 51(1):92-4. PMC: 472809. DOI: 10.1136/thx.51.1.92. View

14.

Toumbis M, Rasidakis A, Passalidou E, Kalomenidis J, Alchanatis M, Orphanidou D . Evaluation of CYFRA 21-1 in malignant and benign pleural effusions. Anticancer Res. 1996; 16(4A):2101-4. View

15.

Villena V, Lopez-Encuentra A, Echave-Sustaeta J . Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients. Cancer. 1996; 78(4):736-40. DOI: 10.1002/(SICI)1097-0142(19960815)78:4<736::AID-CNCR7>3.0.CO;2-C. View

16.

Paone G, de Angelis G, Greco S, Fiorucci F, Bisetti A, Ameglio F . Carcinoembryonic antigen, tissue polypeptide antigen and neuron-specific enolase pleural levels used to classify small-cell and non-small-cell lung cancer patients by discriminant analysis. J Cancer Res Clin Oncol. 1996; 122(8):499-503. DOI: 10.1007/BF01187163. View

17.

Ferrer J, Munoz X, Orriols R, Light R, Morell F . Evolution of idiopathic pleural effusion: a prospective, long-term follow-up study. Chest. 1996; 109(6):1508-13. DOI: 10.1378/chest.109.6.1508. View

18.

Zeimet A, Marth C, Offner F, Obrist P, Uhl-Steidl M, Feichtinger H . Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol. 1996; 62(3):384-9. DOI: 10.1006/gyno.1996.0253. View

19.

Romero S, Fernandez C, Arriero J, Espasa A, Candela A, Martin C . CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur Respir J. 1996; 9(1):17-23. DOI: 10.1183/09031936.96.09010017. View

20.

Garcia-Pachon E, Padilla-Navas I, Dosda M . Elevated level of carcinoembryonic antigen in nonmalignant pleural effusions. Chest. 1997; 111(3):643-7. DOI: 10.1378/chest.111.3.643. View